Bill Liz

The FDA has approved Portola Pharmaceuticals Inc (NASDAQ: PTLA)’s BevyxXa, a blood-thinner for acutely ill patients not undergoing surgery. BevyxXa is the first oral drug of its kind to be approved to help prevent deep vein thrombosis and pulmonary embolisms. Portola shares are halted on the...